CAS 187987-68-4 Gp100(619-627)

Send Inquiry
CAS 187987-68-4 Gp100(619-627)
Details
Human gp100 residues 619-627 epitope;
Category: Tumor differentiation antigen / melanoma CTL epitope.
Peptide Purity (HPLC) ≥95%
CAS No. 187987-68-4
Structure Linear 9-mer (gp100 619-627)
Solubility DMSO/water cosolvent, PBS
Storage Powder, −20°C, dry, light-protected
Category
Epitope Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 187987-68-4 gp100(619-627) in China, also supports custom service. Welcome to wholesale bulk high quality cas 187987-68-4 gp100(619-627) from our factory. Contact us for more details.

 

Description Human gp100/Pmel17 residues 619–627, an HLA-restricted melanoma self-antigen; used for melanoma immunology, vaccines and TIL.

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
Gp100 (619-627) Peptide (human melanoma differentiation antigen gp100/PMEL, RLMKQDFSV, CAS 187987-68-4) RLMKQDFSV; gp100(619-627) free base; PMEL(619-627)/SILV; TargetMol TP1574 / BOC Sciences / Pharmasources GT-183; same-sequence acetate version: PEP-GP100619-01; distinct from gp100(209-217)=ITDQVPFSV and gp100(25-33) Tumor immunology, melanoma, gp100/PMEL differentiation antigen, HLA-A*0201-restricted, CD8 CTL/TIL epitope, cancer vaccine, pMHC tetramer, Met anti-oxidation, free base Linear 9-mer, H-Arg-Leu-Met-Lys-Gln-Asp-Phe-Ser-Val-OH (RLMKQDFSV); residues 619-627 of human melanoma differentiation antigen gp100/PMEL (UniProt P40967), an HLA-A*0201-restricted melanoma CD8+ CTL epitope; located in the C-terminal cytoplasmic-tail region of the 661-aa PMEL precursor; contains 1x Met (position 3) - must be protected against oxidation to methionine sulfoxide; no Cys/Trp/Tyr; CAS 187987-68-4 corresponds to the free-base core (commercial synthetic peptides are routinely supplied as TFA salt; final COA prevails) C49H82N14O14S 1122.59 1123.34 Free base / not specified (CAS 187987-68-4 corresponds to the free-base form RLMKQDFSV; synthetic peptide is routinely supplied as TFA salt, final COA prevails; formula column lists the free core C49H82N14O14S) 9

 

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-GP100619-02 White to off-white powder (standard for synthetic peptides) Store at -20°C, sealed and dry, approx. 2 years; contains 1x Met: seal under nitrogen/inert (argon) atmosphere, keep dry and light-protected to prevent Met oxidation to sulfoxide; free base is less hygroscopic than TFA salt but still moisture-proof; aliquot single-use portions to avoid repeated freeze-thaw Store at 2-8°C, sealed and dry, for approx. 2 weeks; working aliquots at -20°C; ship on blue ice; allow to reach room temperature before opening Hydrophobic nonapeptide with poor water solubility: first prepare a 5-10 mg/mL DMSO stock, then dilute with PBS/culture medium; watch for aggregation. Contains Met: use degassed solvent or add a reducing agent (e.g. 0.5-1 mM TCEP/DTT) to suppress oxidation. Store DMSO aliquots under nitrogen at -20°C and prepare working solutions fresh; typical in vitro pulsing of DCs/target cells at 1-10 ug/mL (approx. 1-10 uM) solid stable approx. 2 years at -20°C, sealed and dry; contains Met: store under nitrogen/inert gas in a desiccator, light-protected; weigh rapidly and reseal promptly after opening

 

Functional Description

 

Product Code Frontend Short Summary Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Receptors
PEP-GP100619-02 Human gp100/PMEL(619-627) nonapeptide RLMKQDFSV free base (CAS 187987-68-4), an HLA-A*0201-restricted melanoma CD8+ CTL epitope for CTL/TIL studies, cancer vaccines and tetramer preparation; contains 1x Met - anti-oxidation required; DMSO co-solvent. RLMKQDFSV, the nonapeptide at residues 619-627 of human melanoma differentiation antigen gp100 (PMEL/SILV, UniProt P40967), is an HLA-A*0201-restricted tumor-associated epitope recognized by melanoma CD8+ cytotoxic T lymphocytes (CTL), located near the C-terminal cytoplasmic tail of the 661-aa PMEL precursor. CAS 187987-68-4 is consistently assigned to this free peptide across TargetMol TP1574, ZellBio, BOC Sciences (>=95% HPLC), Pharmasources GT-183 (MW 1123.33) and BenchChem. Widely used for: (1) in vitro recognition and killing assays of melanoma tumor-infiltrating lymphocytes (TIL) and CTLs; (2) assembly of HLA-A*0201/gp100 pMHC-I tetramers and flow-cytometric staining; (3) epitope screening and immunogenicity evaluation for therapeutic melanoma vaccines; (4) TCR identification and affinity screening for TCR-T cells. This product and the same-sequence acetate version (PEP-GP100619-01) are different salt forms of the same peptide. It is a distinct region of PMEL from the previously handled gp100(209-217)=ITDQVPFSV (the native parent of the enhanced analog IMDQVPFSV) and gp100(25-33), with different sequences, MHC anchor residues and use cases - do not confuse. Note that the catalog candidate RLPRIFCSC is incorrect; UniProt evidence confirms 619-627 = RLMKQDFSV (contains 1x Met, no Cys). Tumor immunology, melanoma, gp100/PMEL differentiation antigen, HLA-A*0201, CTL/TIL research, cancer vaccine, pMHC-I tetramer, TCR-T research Human MHC-I molecule HLA-A*0201 presenting to CD8+ T cells; human melanoma differentiation antigen gp100/PMEL (UniProt P40967)

 

 

 

 

Hot Tags: cas 187987-68-4 gp100(619-627), China cas 187987-68-4 gp100(619-627) manufacturers, suppliers, factory, 124454-83-7, 265669-37-2, CAS 125366 42 9, CAS 265669 37 2, epitope peptides, Nucleoprotein 118 126

Send Inquiry